Kevin Tan
Chief Financial Officer
Replay available
Selecta Biosciences, Inc. (SELB) Q1 2022 Earnings Call
Selecta Biosciences, Inc. (NASDAQ: SELB) Q1 2022 earnings conference call, held 2022-05-05. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Carson Bruin
President and Chief Executive Officer
Peter Traber
Chief Medical Officer
Kate Kishimoto
Chief Scientific Officer
John Newman
Analyst, Canaccord
Yun Zhang
Analyst, BTIG
Raju Prasad
Analyst, William Blair
Mr. Oiir
Analyst, Mizuho
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Cartesian Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.029 -- 00:00:05.432 Good morning, and welcome to the Selecta Biosciences first quarter 2022 financial 00:00:05.432 -- 00:00:08.354 results and corporate update conference call. 00:00:08.354 -- 00:00:12.137 Currently, all participants are in a listen-only mode. 00:00:12.137 -- 00:00:16.860 This call is being webcast live on the investors and media section of Selecta's website 00:00:16.860 -- 00:00:19.400 at www.selectabio.com, 00:00:20.602 -- 00:00:25.625 and it is being recorded. For opening remarks, I would like to introduce Kevin Tan, 00:00:25.625 -- 00:00:29.244 Chief Financial Officer of Selecta. Please go ahead. 00:00:29.244 -- 00:00:33.626 Thank you and good morning. Welcome to our first quarter 2022 00:00:33.626 -- 00:00:37.628 financial results and corporate update conference call. 00:00:37.628 -- 00:00:41.730 The press release reporting our financial results is available in the investors and media 00:00:41.730 -- 00:00:45.871 section of Selective's website, worldwidewebselectivebio.com. 00:00:46.833 -- 00:00:53.405 And our quarterly report on form 10Q for the quarter ended March 31st, 2022, 00:00:53.676 -- 00:00:59.398 which will be filed today with the Securities and Exchange Commission or SEC. 00:00:59.445 -- 00:01:04.548 Joining me today are Carson Bruin, President and Chief Executive Officer, 00:01:04.548 -- 00:01:11.390 Peter Traber, Chief Medical Officer, and Kate Kishimoto, Chief Scientific Officer. 00:01:11.451 -- 00:01:16.134 During today's call, we will be making certain forward-looking statements, including, 00:01:16.134 -- 00:01:21.456 without limitation, statements about the potential safety, efficacy, 00:01:21.456 -- 00:01:27.199 and regulatory and clinical progress of our product candidates, financial projections, 00:01:27.199 ...